N- (2- hydroxyethyl)- 4- (beta- (1- naphthylvinyl)pyridinium bromide) (B111)

inhibitor of choline acetyltransferase & synthesis of acetylcholine in neuroblastoma cells; RN given refers to bromide

Also Known As:

B111; B 111; 4-(1-naphthylvinyl)pyridine hydroxyethyl bromide; N-(2-hydroxyethyl)-4-(beta-(1-naphthylvinyl)pyridinium bromide), (trans-(E))-isomer

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chen, Xiao-Li: 1 article (05/2020)
2.	Liu, Li: 1 article (05/2020)
3.	Wang, Yan: 1 article (05/2020)
4.	Wei, Xin-Ran: 1 article (05/2020)
5.	Wu, Xue-Fen: 1 article (05/2020)
6.	Yue, Zeng-Hui: 1 article (05/2020)
7.	Zheng, Xue-Na: 1 article (05/2020)
8.	Chang, Hee-Kyung: 1 article (01/2020)
9.	Gil, Cho-Rong: 1 article (01/2020)
10.	Kim, Mi-Kyoung: 1 article (01/2020)

Related Diseases

1.	Sleep Initiation and Maintenance Disorders (Insomnia) 05/12/2020 - "A total of 333 patients with primary insomnia were recruited from 3 study centers and randomly divided into a group A (111 cases, 7 cases dropped off), a group B (111 cases, 5 cases dropped off) and a group C (111 cases, 2 cases dropped off). "
2.	Sarcopenia 01/01/2020 - "The overall prevalence of sarcopenia was 41.0% by the AWGS-recommended algorithm, 37.6% by algorithm A, and 37.6% by algorithm B; 111 participants were diagnosed with sarcopenia using all three methods (p = 0.157). "
3.	Hypersensitivity (Allergy) 12/01/1976 - "A marked inhibitory action of globulins obtained from human serum of the B (111) blood group on the allergic reactions of the immediate type was shown. "
4.	Coronary Disease (Coronary Heart Disease) 06/01/2005 - "Atorvastatin treatment compared to placebo resulted in a significant decrease in serum cholesterol (5.85 +/- 1.04 mmol/l vs. 4.22 +/- 0.69 mmol/l; mean +/- SD; P < 0.001), low-density lipoprotein (LDL) cholesterol (2.95 +/- 1.07 mmol/l vs. 1.82 +/- 0.92 mmol/l; P < 0.001), very low-density lipoprotein (VLDL) cholesterol (0.31 (0.21-0.47) mmol vs. 0.23 (0.13-0.30) mmol/l median (interquartile range); P < 0.05), apolipoprotein B (111 +/- 28 mg/dl vs. 80 +/- 18 mg/dl; P < 0.001), and calculated coronary heart disease risk (6.8 (3.3-17.9) vs. 2.8 (1.5-5.7)% over next 10 years; P < 0.01). "

Related Drugs and Biologics

1.	VLDL Cholesterol
2.	VLDL Lipoproteins
3.	LDL Cholesterol
4.	LDL Lipoproteins (beta Lipoproteins)
5.	Globulins
6.	Cholesterol
7.	Blood Group Antigens (Blood Groups)
8.	Apolipoproteins
9.	Atorvastatin (Lipitor)